Fig. 7

IFN-β treatment inhibits the replication of ZIKV in hNSCs. a Human NSCs were treated with different doses of IFN-β protein and then infected with ZIKV. The cellular viability was assessed by MTT assay. The experiments were performed in triplicate, and the error bars represented the SD. The two-way ANOVA was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. b Immunofluorescence staining was performed to detect the expression of ZIKV E protein in ZIKV-infected hNSCs that were treated with different doses of IFN-β protein. c RT-qPCR analysis was performed to detect ZIKV vRNA in ZIKV-infected hNSCs that treated with different doses of IFN-β. The experiments were performed in triplicate, and the error bars represented the SD. Student’s t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. d Growth curves of ZIKV in hNSCs treated with 0, 0.1, and 1 ng/ml IFN-β. The experiments were performed in triplicate, and the error bars represented the SD. The two-way ANOVA was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. e Human NSCs were infected with ZIKV at an MOI of 1, and then anti-IFN-β antibody (100 ng/ml and 500 ng/ml) was added to the cells after virus adsorption. Total RNA was harvested at 24 h post-infection, and RT-qPCR was performed to detect the virus RNA. The experiments were performed in triplicate, and the error bars represented the SD. Student’s t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001